Chembio Diagnostics (Chembio Diagnostics) Debt-to-Asset : 0.40 (As of Dec. 2022)

View and export this data going back to 2004. Start your Free Trial

What is Chembio Diagnostics Debt-to-Asset?

Chembio Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $19.57 Mil. Chembio Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $5.51 Mil. Chembio Diagnostics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was $62.61 Mil. Chembio Diagnostics's debt to asset for the quarter that ended in Dec. 2022 was 0.40.

Chembio Diagnostics Debt-to-Asset Historical Data

The historical data trend for Chembio Diagnostics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chembio Diagnostics Debt-to-Asset Chart

Chembio Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.46

0.39

0.35

0.40

Chembio Diagnostics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Asset	Get a 7-Day Free Trial															0.35	0.41	0.47	0.41	0.40

Competitive Comparison of Chembio Diagnostics's Debt-to-Asset

For the Diagnostics & Research subindustry, Chembio Diagnostics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chembio Diagnostics's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Chembio Diagnostics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Chembio Diagnostics's Debt-to-Asset falls into.

Chembio Diagnostics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Chembio Diagnostics's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(19.569	+	5.513)	/	62.611
	=	0.40

Chembio Diagnostics's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(19.569	+	5.513)	/	62.611
	=	0.40

Chembio Diagnostics (NAS:CEMI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Chembio Diagnostics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Chembio Diagnostics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Chembio Diagnostics (Chembio Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Chembio Diagnostics Inc (NAS:CEMI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3661 Horseblock Road, Medford, NY, USA, 11763

Website

http://www.chembio.com

Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases. The products of the company include rapid tests for the detection of HIV 1/2 antibodies and a multiplex rapid test for the detection of HIV and syphilis antibodies. The company offered rapid medical tests that are offered in Africa, Asia, Europe, and the Middle East, Latin America and the United States, of which key revenue is derived from Latin America.

Executives

Perceptive Credit Advisors, Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Leslie Teso-lichtman	director	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Charles Caso	officer: See remarks	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Paul Angelico	officer: See remarks	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Lawrence J. Steenvoorden	officer: See remarks	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
David William Bespalko	director	29 CEDAR DRIVE, ALLENDALE NJ 07401
David Acheson	director	C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD, HAUPPAUGE NY 11788
Richard Eberly	officer: See Remarks	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John Gary Potthoff	director	6140 SPANISH OAKS CLUB BLVD., AUSTIN TX 78738
Javan Esfandiari	officer: Senior Vice President	3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Robert Passas	officer: See Remarks	3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Polan Mary Lake Ph D	director	STANFORD UNIVERSITY SCHOOL OF MEDICINE, 300 PASTAUR DR ROOM HH333, STANFORD CA 94305-5317
Neil A Goldman	officer: Executive VP and CFO	3661 HORSEBLOCK RD, MEDFORD NY 11763